BML Capital Management LLC Sells 6,537 Shares of CalciMedica, Inc. (NASDAQ:CALC)

BML Capital Management LLC lessened its holdings in CalciMedica, Inc. (NASDAQ:CALC) by 4.1% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 153,887 shares of the company’s stock after selling 6,537 shares during the period. CalciMedica comprises approximately 0.4% of BML Capital Management LLC’s holdings, making the stock its 22nd biggest position. BML Capital Management LLC’s holdings in CalciMedica were worth $682,000 at the end of the most recent quarter.

Separately, Atria Investments Inc lifted its stake in shares of CalciMedica by 136.5% in the 3rd quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock worth $117,000 after purchasing an additional 15,296 shares during the period.

Insider Transactions at CalciMedica

In other news, CEO A. Rachel Leheny acquired 20,000 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were acquired at an average cost of $3.75 per share, with a total value of $75,000.00. Following the completion of the acquisition, the chief executive officer now owns 130,926 shares of the company’s stock, valued at approximately $490,972.50. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. In other CalciMedica news, CEO A. Rachel Leheny purchased 20,000 shares of the stock in a transaction on Friday, November 1st. The shares were bought at an average price of $3.75 per share, for a total transaction of $75,000.00. Following the completion of the transaction, the chief executive officer now owns 130,926 shares of the company’s stock, valued at $490,972.50. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Robert N. Wilson bought 54,000 shares of CalciMedica stock in a transaction on Friday, August 23rd. The shares were purchased at an average cost of $3.72 per share, with a total value of $200,880.00. Following the acquisition, the director now directly owns 364,196 shares of the company’s stock, valued at approximately $1,354,809.12. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders purchased 312,944 shares of company stock valued at $1,172,910. Corporate insiders own 41.55% of the company’s stock.

CalciMedica Stock Down 1.1 %

CALC traded down $0.04 during trading hours on Tuesday, reaching $3.46. 9,764 shares of the company’s stock traded hands, compared to its average volume of 36,100. The firm has a 50-day moving average price of $4.17 and a 200 day moving average price of $4.59. CalciMedica, Inc. has a 52-week low of $2.68 and a 52-week high of $8.38. The firm has a market capitalization of $37.20 million, a PE ratio of -2.50 and a beta of 1.30.

CalciMedica (NASDAQ:CALC) last issued its earnings results on Monday, August 12th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.03. Equities analysts predict that CalciMedica, Inc. will post -2.21 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright lowered their price objective on shares of CalciMedica from $20.00 to $16.00 and set a “buy” rating on the stock in a research note on Monday, November 4th.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.